What we do
Stemina is the world leader in building human cellular models for toxicity screening of drug candidates, chemical compounds, cosmetic and tobacco ingredients. Our developmental toxicity assays are the only human system for assessing the risk that a compound will cause birth defects if a woman is exposed during pregnancy.

What we do


Stemina's toxicology assays are the only human in vitro assays for developmental toxicity screening.



Stemina's metabolomics platform and expertise in cellular models can be used for custom projects.


Our Team

Stemina has assembled a world class team of scientists and experts. Meet our team.


Latest news

Jan 18

NeuroPointDX Announces Validation of First-Generation Autism Diagnostic Panel

Jan 18, 2018
NeuroPointDX, the neurodevelopmental disorders division of Stemina Biomarker Discovery, has validated 12 metabolic subtypes of autism spectrum disorder. The diagnostic blood test for ASD will be available later this year. CEO Elizabeth Donley says, “This is a historic moment, not just for Stemina and NeuroPointDX, but for our knowledge and understanding of autism.” Read the

Read more
Oct 25

Stemina to Present a Poster at American College of Toxicology Annual Meeting

Oct 25, 2017
Jessica Palmer, Stemina’s Associate Director of Toxicology, will present a poster at the American College of Toxicology’s 38th Annual Meeting, held November 5-8, 2017 in Palm Springs, California. Anyone interested in cardiotoxicity assays is encouraged to attend. Development of a Targeted Biomarker Assay to Predict Cardiotoxicity Potential Using Metabolomics and Human Induced Stem Cell-Derived Cardiomyocytes

Read more
Sep 27

Stemina Featured as an Innovative Madison-Area Business

Sep 27, 2017
In collaboration with the Greater Madison Chamber of Commerce, the Wisconsin State Journal produced a special section to “highlight and explore innovation efforts.” Each company’s profile is written by its leader. Stemina’s CEO, Elizabeth Donley, penned our article and also graces the cover of the section. Read Stemina’s profile Explore other companies in the section

Read more